Zacks Investment Research on MSN1d
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly ...
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
Vertex non-opioid painkiller Journavx gets mixed ICER review
ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...
Pharmaceutical Technology on MSN2d
Vertex halts development of diabetes cell therapy after trial failure
Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.
GitHub18d
rpg-maker-vxace
Tool for decrypting and extracting RPG Maker XP, VX and VX Ace encrypted archives and MV and MZ encrypted files. Open-source cross-platform player for (some) RPG Maker XP / VX / VX Ace games. A very ...
The Motley Fool23d
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
BioPharma Dive28d
Vertex’s new pain drug gets first coverage nod from major insurer
Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...